




RealRate

PHARMACEUTICAL 2015

Melinta Therapeutics INC NEW
Rank 169 of 274



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2015

Melinta Therapeutics INC NEW Rank 169 of 274

The relative strengths and weaknesses of Melinta Therapeutics INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Melinta Therapeutics INC NEW compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Melinta Therapeutics INC NEW is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 27% points below the market average of 254%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	104,851	Assets	105,311
Cost of Goods Sold	0	Liabilities	44,290
Intangible Assets	0	Expenses	74,616
Liabilities, Current	18,086	Revenues	15,216
Liabilities, Non-Current	14,878	Stockholders Equity	61,021
Other Assets	346	Net Income	-61,649
Other Compr. Net Income	0	Comprehensive Net Income	-61,649
Other Expenses	0	BaseVar	120,841
Other Liabilities	11,326	ECR before LimitedLiability	95%
Other Net Income	-2,249	Economic Capital Ratio	227%
Other Revenues	15,216		
Property and Equipment	113		
Research and Development	62,539		
Selling, General and Administrative Expense	12,077		